Unintended weight loss is a hallmark of Huntington disease (HD), but it is unknown to what extent weight loss impacts the rate of disease progression. Therefore, using longitudinal data from the Enroll-HD study, we assessed the association between baseline body mass index (BMI) and the rate of clinical progression in 5,821 HD mutation carriers. We found that high baseline BMI was associated with a significantly slower rate of functional, motor, and cognitive deterioration (all p < 0.001), independent of mutant HTT CAG repeat size. Our findings provide strong rationale for exploration of systemic metabolism as a therapeutic target in HD. ANN NEUROL 2017;82:479-483 H untington disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene resulting in a long polyglutamine tract in the N-terminus of the encoded protein huntingtin.
Unintended weight loss is a hallmark of Huntington disease (HD), but it is unknown to what extent weight loss impacts the rate of disease progression. Therefore, using longitudinal data from the Enroll-HD study, we assessed the association between baseline body mass index (BMI) and the rate of clinical progression in 5,821 HD mutation carriers. We found that high baseline BMI was associated with a significantly slower rate of functional, motor, and cognitive deterioration (all p < 0.001), independent of mutant HTT CAG repeat size. Our findings provide strong rationale for exploration of systemic metabolism as a therapeutic target in HD. ANN NEUROL 2017; 82:479-483 H untington disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene resulting in a long polyglutamine tract in the N-terminus of the encoded protein huntingtin. 1 Apart from motor, cognitive, and behavioral disturbances, a hallmark of the disease is unintended weight loss, in both HD patients and premanifest mutation carriers, 2, 3 as well as various genetic animal models of the disease. [4] [5] [6] Previously, we found that weight loss in HD patients increases with larger mutant HTT CAG repeat size, 2 and others reported higher caloric intake in premanifest mutation carriers with increasing CAG repeat length. 7 These findings suggest a hypermetabolic state in HD, which worsens with larger mutant HTT CAG repeat size, possibly due to a polyglutamine length-dependent interference of mutant huntingtin with cellular energy production. 4 Although in a small study higher body mass index (BMI) was found to be associated with slower disease progression, 8 subsequent investigations in somewhat larger cohorts could not confirm this finding. 9, 10 Therefore, despite resulting in general weakening and a decline in the quality of life, 4 it is still unknown to what extent weight loss influences disease progression in HD. Elucidation of the association between body weight and disease progression, however, is of paramount importance, as it would not only allow for a better prediction of disease course but could also provide a strong rationale for further exploration of promising energy-based treatments as potential therapeutic targets in HD. 11, 12 In this study, we therefore aimed to provide an accurate and conclusive estimate of the association between body weight and the rate of progression on the most important clinical domains of HD using longitudinal data from the largest cohort currently available.
Patients and Methods

Observational Cohort Study
PARTICIPANTS. For assessing the association between BMI (defined as body weight in kilograms divided by the square of height in meters) and disease progression, we used monitored data from 5,821 individuals (54% female) participating in the Enroll-HD study, which also included longitudinal data from 2,488 individuals who had previously participated in the REG-ISTRY study. 13, 14 All participating sites were required to obtain and maintain local ethics committee approvals, and all participants gave signed informed consent for their data to be included. 13, 14 We retrieved all data from the Enroll-HD website on February 17, 2017, and included all participants with a mutant CAG repeat size of 36 in our analysis. 14 
Statistical Analyses
We applied linear mixed-effects models with both fixed and random terms for disease duration to account for the correlation between the repeated measurements for each individual, using an unstructured variance-covariance matrix. 15 First, we assessed the rate of weight loss by including BMI as the dependent variable and sex, age of onset (defined as the age at clinical diagnosis), disease duration, and mutant CAG repeat size as independent variables. Next, we also included an interaction term between disease duration and mutant CAG repeat size to quantify the effect of CAG repeat size on the rate of weight loss. Subsequently, we assessed the effect of baseline BMI (defined as the first BMI measurement recorded for each subject) on measures of disease progression, including the Unified Huntington Disease Rating Scale (UHDRS) total functional capacity (TFC), total motor score (TMS), and all available UHDRS cognitive subscores. In addition, we performed a principal components analysis on the 6 UHDRS cognitive subdomains to derive a unique summary statistic that could capture most of the variation in the cognitive scores. This analysis resulted in 6 factors, of which the first (principal component 1 [PC1]) accounted for 80.9% of the variation, whereas the other factors each accounted for 6.5% or less of the variation. Therefore, we also used PC1 as a dependent variable. Each measure of disease progression was treated as the dependent variable, whereas disease duration, baseline BMI as well as its interaction with disease duration, sex, age of onset, and mutant CAG repeat size as well as its interaction with disease duration were included as independent variables. For subgroup analyses, we divided the cohort based on baseline BMI in underweight, normal weight, overweight, obese, and morbidly obese individuals according to the World Health Organization cutoff points of (Fig 1) .
Baseline BMI Is a Significant Predictor of Disease Progression
Mean baseline TFC score was 9.9 6 3.4, decreasing by 0.53 points per year (95% CI 5 20.51 to 20.55). Each unit increase of baseline BMI was associated with 0.012 points/yr slower decline on the TFC scale (95% CI 5 0.008-0.016, p < 0.001; Fig 2A) . The average TMS score at baseline was 24.7 6 21.4, increasing by 3.25 points per year (95% CI 5 3.14-3.36). Each unit increase in baseline BMI was related to a 0.059-points/yr slower rate of deterioration on the TMS scale (95% CI 5 20.080 to 20.037, p < 0.001; see Fig 2B) .
As expected, all UHDRS cognitive subscores significantly deteriorated during the follow-up period (Table) . Higher baseline BMI was associated with a slower rate of decline on all UHDRS cognitive subdomains as well as the cognitive summary score represented by PC1 (see Table and Fig 2C) .
Sensitivity and Subgroup Analyses
Given that our primary analyses were based on the entire dataset, which also contained individuals who were underweight (n 5 203) or morbidly obese (n 5 96; see Figs 1 and 2) , we also performed a sensitivity analysis by repeating the calculations after exclusion of these individuals. The results did not change materially and remained statistically significant (data not shown). Similarly, adjustment for disease stage at baseline, as represented by the TFC score, did not change the statistical significance of the results (data not shown). Compared to normal weight participants and after adjustment for sex, age of onset, disease duration, and CAG repeat size: (1) in underweight individuals, mean TFC score was lower and mean TMS score was higher by 1.12 and 7.82 points, respectively (both p < 0.001); (2) in overweight, obese, and morbidly obese individuals, mean TMS scores were lower by 2.29, 4.36, and 7.04 points, respectively (all p < 0.01); and (3) the rates of functional and motor deterioration were significantly slower in (morbidly) obese individuals, and the rate of cognitive deterioration was slower in overweight and obese participants (all p < 0.01).
Discussion
Using high-quality, longitudinal data from the largest cohort of HD mutation carriers available to date, here we present conclusive evidence for an association between body weight and the rate of disease progression in HD. Patients with a high BMI at baseline exhibited a slower rate of progression on all clinical domains that are known to deteriorate with longer disease duration in HD, including functional capacity, motor function, and cognitive performance. In addition, we provide more precise estimates of the strong length-dependent detrimental effect of mutant HTT CAG repeat size on body weight and the rate of weight loss, validating and extending our previous findings. 2 Importantly, however, the association between BMI and disease progression was independent of mutant CAG repeat size, indicating that factors other than CAG repeat size must account for this relation. Until now, reports regarding a possible link between body weight and disease progression in HD have been discrepant. Although Myers et al were the first to identify a high BMI as a predictor of slower progression in a group of 42 patients with HD, 8 it is unknown to what extent baseline differences in mutant HTT CAG repeat size, which is strongly associated with both BMI FIGURE 2: Higher baseline body mass index (BMI) is associated with slower disease progression in Huntington disease. A higher BMI at baseline was associated with a slower rate of progression on all assessed clinical domains in patients with Huntington disease, including total functional capacity (A), total motor score (B), and a cognitive summary score represented by PC1 (C; please refer to the text for details). All estimates were adjusted for sex, age of onset, and mutant CAG repeat size. Each point represents 1 subject, and the shaded areas around the regression lines indicate the 95% confidence intervals around the estimates.
van der Burg et al: Weight and Progression in HD and disease progression, 2 might have accounted for their findings. Moreover, subsequent studies found no clear association between body weight and disease progression. 9, 10 However, unequivocal interpretation of these previous reports is further limited because most of them involved relatively small-scaled studies that were performed before the introduction of the UHDRS, a rating scale that standardized clinical assessment in HD and thereby allowed for a more accurate evaluation of disease progression. 16 Taking advantage of a much larger cohort of HD mutation carriers who were systematically and uniformly followed up for a considerable amount of time, here we show that a relatively high BMI is a robust and consistent predictor of disease progression in HD. Importantly, the effect of BMI was seen on all clinical measures of progression in HD, including functional and motor impairment and decline on all cognitive subdomains of the UHDRS. As the mechanisms governing the rate of motor and cognitive decline in HD are likely to be central, it is tempting to speculate that the association between BMI and disease progression in HD might be due to an effect of disturbances of energy-regulating mechanisms on central nervous system function. 4 Dysregulation of energy homeostasis in HD could be mediated through pathology of central energy-regulating structures, especially the hypothalamus, which is known to be affected in HD, 17, 18 or might arise from cellular alterations engendered by mutant huntingtin expression in peripheral tissues. 19 Our study has certain limitations. First, although our findings indicate that BMI is a strong predictor of disease progression in HD, the observational nature of our study does not permit for direct conclusions regarding the directionality or causality of this association. Second, data on body composition were not collected, precluding a further characterization of which body weight components (ie, fat free or fat mass) mediate the largest effect. 20 In conclusion, we found that a high BMI was associated with a slower rate of disease progression in HD independent of mutant HTT CAG repeat size and disease stage. These findings thus suggest that systemic metabolism could influence clinical progression in HD, and should therefore be further explored as a potential target area for therapeutic interventions aiming to modify the rate of progression of HD.
